Double-stranded RNA (dsRNA) detection

Detecting and quantifying double-stranded RNA (dsRNA) is a critical analytical challenge in mRNA therapeutic development. dsRNA is a potent immunogen, making its accurate measurement essential for product safety. This post outlines the key analytical methods used, ranging from highly sensitive immunological assays to advanced sequencing and mass spectrometry techniques. Each method offers distinct advantages in terms of sensitivity, specificity, and throughput, and often, a combination of approaches is required for comprehensive characterization and robust quality control.

Legacy: Early detection often relied on less specific methods like gel electrophoresis or non-specific dye binding, which lacked the sensitivity needed for trace impurities.

Current Standard: J2-based ELISA is the most widely used method for routine quantification, often complemented by orthogonal assays for confirmation

Future: Emerging approaches such as NGS and LC-MS of enriched fractions can provide deeper structural characterization of dsRNA species, though currently applied primarily in development and characterization.

Several distinct scientific principles are employed for dsRNA detection:

Immunological (J2-based ELISA & Dot Blot): These methods utilize the monoclonal antibody J2 (or K1), which specifically binds to long stretches of dsRNA (≥40 bp) in a sequence-independent manner.

• ELISA: dsRNA in the sample is captured by a J2 antibody coated on a plate. A secondary enzyme-linked antibody then binds, and a substrate is added to produce a colorimetric or fluorescent signal proportional to the dsRNA concentration.
• Dot Blot: Sample is blotted directly onto a membrane, followed by J2 antibody binding and detection. This is often qualitative or semi-quantitative.

Chromatographic Fractionation: dsRNA, due to its distinct structural properties. Common separation formats include anion-exchange chromatography (AEX) and cellulose-based resins.

Mass Spectrometry (LC-MS of Enriched Fractions): After enrichment, dsRNA fractions can be enzymatically digested. The resulting fragments are analyzed by LC-MS to identify and quantify specific dsRNA sequences.

Next-Generation Sequencing (NGS): NGS approaches identify and quantify dsRNA by analyzing sequences that form stable double-stranded structures or that derive from known aberrant transcripts.

• ELISA: An absorbance or fluorescence signal is converted to a dsRNA concentration (e.g., ng/µg mRNA) using a standard curve.
• Chromatography: Provides chromatograms showing the separation of dsRNA from ssRNA.
• LC-MS: Generates mass spectra allowing for identification of specific dsRNA oligonucleotides.
• NGS: Produces millions of sequence reads, which are analyzed with bioinformatics tools to identify potential dsRNA-forming regions.

• J2 ELISA: High sensitivity (low ng/µg), good specificity for long dsRNA, high throughput, and widely accepted.
• Chromatographic fractionation (e.g., AEX, cellulose resins): Effective for enriching dsRNA, allowing for orthogonal detection and potentially removal.
• LC-MS & NGS: Provide highly specific structural information and broad detection capability, including unexpected or novel dsRNA species.

• J2 ELISA/Dot Blot: May not efficiently detect very short dsRNA. Can be subject to matrix effects.
• Chromatography: Can be labor-intensive and may have limited resolution for very similar species.
• LC-MS & NGS: Complex, low throughput, expensive. Typically used as characterization tools, not for routine QC.

For GMP-compliant methods: For release testing, regulators expect a validated immunoassay (e.g., J2 ELISA). Chromatography, LC-MS, and NGS are applied as characterization or investigational tools, not routine QC.

Specificity: Confirming the assay only detects dsRNA and does not cross-react with ssRNA or other process components.

Sensitivity: Determining the Limit of Detection (LOD) and Limit of Quantitation (LOQ) for relevant dsRNA species.

Accuracy & Precision: Demonstrating the method's ability to provide accurate and reproducible quantification.

Robustness: Assessing the impact of minor method variations on results.

Suitability: Proving the method is fit for its intended purpose (e.g., release testing).

Standardization is challenging due to dsRNA's heterogeneity. Synthetic poly(I:C), a well-characterized synthetic dsRNA, is typically used as a reference standard for J2-based assays. However, its behavior may differ from process-generated dsRNA, so qualification of in-house reference materials is also common.

These dsRNA detection methods are essential across all mRNA therapeutic modalities, including:

• mRNA Vaccines: Ensuring minimal immunogenicity and optimal safety.
• mRNA Therapeutics (e.g., protein replacement, gene editing): Mitigating unwanted immune responses that could limit product efficacy or lead to adverse events.
• Self-Amplifying RNA (saRNA): Particularly important here, as saRNA's replication mechanism has a higher potential for dsRNA formation.